<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2900">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04460027</url>
  </required_header>
  <id_info>
    <org_study_id>56439</org_study_id>
    <nct_id>NCT04460027</nct_id>
  </id_info>
  <brief_title>W-SUDs for COVID-19</brief_title>
  <official_title>Woebot for Substance Use Disorders During COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Athena Robinson</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Woebot Labs, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the efficacy of a substance use disorder intervention
      delivered via a mobile application in an adult population during the COVID-19 pandemic.

      This study that will test the comparative efficacy of the mobile-app based substance use
      disorder program to reduce substance use relative to a wait list control condition, and
      explore between group differences on quality of life indices as well as retention and
      engagement during COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of number of days drinking</measure>
    <time_frame>Difference between baseline and post-treatment (8 weeks from baseline)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of number of days drug use</measure>
    <time_frame>Difference between baseline and post-treatment (8 weeks from baseline)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5 (AUDADIS-V)</measure>
    <time_frame>Difference between baseline and post-treatment (8 weeks from baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Inventory of Problems - Alcohol and Drugs (SIP-AD)</measure>
    <time_frame>Difference between baseline and post-treatment (8 weeks from baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Abuse Screening Test (DAST-10)</measure>
    <time_frame>Difference between baseline and post-treatment (8 weeks from baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Situational Confidence Questionnaire (BSCQ)</measure>
    <time_frame>Difference between baseline and post-treatment (8 weeks from baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Craving rating</measure>
    <time_frame>Difference between baseline and post-treatment (8 weeks from baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain rating</measure>
    <time_frame>Difference between baseline and post-treatment (8 weeks from baseline)</time_frame>
    <description>Range from 0-100 (no pain to worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire-9 (PHQ-9)</measure>
    <time_frame>Difference between baseline and post-treatment (8 weeks from baseline)</time_frame>
    <description>Total score between 0-27, higher scores indicate greater levels of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Anxiety Disorder-7 (GAD-7)</measure>
    <time_frame>Difference between baseline and post-treatment (8 weeks from baseline)</time_frame>
    <description>Total score between 0-21, higher scores indicate greater levels of anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAIR Pandemic Impact Questionnaire (CAIR-PIQ)</measure>
    <time_frame>Difference between baseline and post-treatment (8 weeks from baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Client Satisfaction Questionnaire (CSQ)</measure>
    <time_frame>Post-treatment (8 weeks from baseline)</time_frame>
    <description>Range from 8 to 32, with higher values indicating higher satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage Rating Profile Intervention (URPI)</measure>
    <time_frame>Post-treatment (8 weeks from baseline)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Substance Use Disorders</condition>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>W-SUDs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait List Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Woebot Substance Use Disorder</intervention_name>
    <description>Woebot Substance Use Disorder is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.</description>
    <arm_group_label>W-SUDs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All genders aged 18-65 years

          -  Access to a smartphone

          -  Available and committed to engage with app and complete assessments

          -  Be willing to provide email address (as this is how assessment incentives will be
             distributed),

          -  Literate in English (as W-SUDs conversational and video materials will be in English).

        Exclusion Criteria:

          -  Pregnancy (as W-SUDs will not be specifically developed to address the unique needs of
             this population)

          -  History of severe drug/alcohol use

          -  History of opioid misuse without medication-assisted treatment

          -  Suicide attempt within the past year

          -  Opioid overdose within the past year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Prochaska</last_name>
      <phone>650-724-3608</phone>
      <email>surveys4health@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Woebot Labs, Inc.</investigator_affiliation>
    <investigator_full_name>Athena Robinson</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

